Volume 11,Issue 4
Analysis of Factors Influencing Disease Outcomes in Patients with Liver Cirrhosis and Upper Gastrointestinal Hemorrhage After Endoscopic Hemostasis
Objective: To investigate the factors influencing disease outcomes in patients with liver cirrhosis and upper gastrointestinal hemorrhage (UGH) after endoscopic hemostasis. Methods: A retrospective analysis was conducted on clinical data of patients with liver cirrhosis and UGH admitted to our hospital from January 2023 to December 2024. All patients received endoscopic hemostasis. According to their disease outcomes, 215 patients were divided into a good prognosis group (172 cases) and a rebleeding group (43 cases, with rebleeding occurring one year after treatment). The influencing factors for disease outcomes were analyzed. Results: The rate of good prognosis in patients with liver cirrhosis and UGH was 80.00%, and the one-year rebleeding rate after treatment was 20.00%. Univariate analysis showed that age, liver cirrhosis stage, liver function grade, hepatic encephalopathy, esophageal varices, complications, and shock index were influencing factors for disease outcomes in these patients (P < 0.05). Binary logistic regression analysis showed that age, decompensated liver cirrhosis, hepatic encephalopathy, esophageal varices, and complications were independent risk factors for rebleeding one year after treatment (P < 0.05). Conclusion: One year after endoscopic hemostasis, patients with liver cirrhosis and UGH have a relatively high rebleeding rate. Factors such as bleeding volume influence disease outcomes. Therefore, increased attention and targeted interventions are needed to achieve better prognostic outcomes.
[1] Bendtsen F, Larsen FS, Ott P, et al., 2014, Cirrhosis of the Liver. Ugeskr Laeger, 176(4): V02130126.
[2] Zhao H, Zhao R, Hu J, et al., 2019, Upper Gastrointestinal Hemorrhage in Acute-on-Chronic Liver Failure: Prevalence, Characteristics, and Impact on Prognosis. Expert Rev Gastroenterol Hepatol, 13(3): 263–269.
[3] Manno M, Mangiafico S, Caruso A, et al., 2016, First-Line Endoscopic Treatment with OTSC in Patients with High-Risk Non-Variceal Upper Gastrointestinal Bleeding: Preliminary Experience in 40 Cases. Surg Endosc, 30(5): 2026–2029.
[4] Chinese Society of Hepatology, Chinese Medical Association, 2019, Guidelines for the Diagnosis and Treatment of Liver Cirrhosis. Chinese Journal of Hepatology, 27(11): 846–865.
[5] Emergency Physicians Branch of Chinese Medical Doctor Association, Emergency Medicine Branch of Chinese Medical Association, Professional Committee of Emergency Medicine of the Whole Army, et al., 2021, Expert Consensus on Emergency Diagnosis and Treatment Process of Acute Upper Gastrointestinal Bleeding. Chinese Journal of Critical Care Medicine, 41(1): 1–10.
[6] Butterworth RF, 2019, Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology. Drugs, 79(Suppl 1): 17–21.
[7] Swarna A, Ramamoorthy M, Kini R, et al., 2023, Platelet-Albumin-Bilirubin Score - A Risk Stratification Scoring System to Predict Outcome of Acute Variceal Bleeding in Patients with Cirrhosis. Eur J Gastroenterol Hepatol, 35(9): 1044–1048.
[8] Tripathi H, Benjamin J, Maiwall R, et al., 2022, Identifying Critically Ill Patients with Cirrhosis who Benefit from Nutrition Therapy: The mNUTRIC Score Study. J Clin Transl Res, 8(5): 425–433.
[9] Peng J, Jin H, Zhang N, et al., 2025, Development and Evaluation of a Predictive Model of Upper Gastrointestinal Bleeding in Liver Cirrhosis. BMC Gastroenterol, 25(1): 142.
[10] Li Y, Li H, Zhu Q, et al., 2019, Effect of Acute Upper Gastrointestinal Bleeding Manifestations at Admission on the In-Hospital Outcomes of Liver Cirrhosis: Hematemesis Versus Melena Without Hematemesis. Eur J Gastroenterol Hepatol, 31(11): 1334–1341.
[11] Jiang H, Zhao Z, Cui S, et al., 2025, Prognostic Factors for Mortality in Patients with Acute-on-Chronic Liver Failure. Eur J Gastroenterol Hepatol, 37(7): 833–843.